Increased HIV-1 infection in PBMCs treated in vitro with menstrual cycle phase hormones or medroxyprogesterone acetate likely occurs via different mechanisms.
Alexis J BickChanel AvenantMichele TomasicchioZephne Margeret van der SpuyJanet P HapgoodPublished in: American journal of reproductive immunology (New York, N.Y. : 1989) (2022)
MPA increases HIV-1 infection in a manner different from that of luteal phase hormones, most likely involving the GR and at least in part changes in the frequency and/or expression of CCR5 and CD69.